Podcasts about Novo Nordisk

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über den neuen Drohnen-Liebling, einen Bitcoin-Rekord und die Rückkehr des Wasserstoff-Hypes. Außerdem geht es um Volatus Aerospace, WK Kellog, EssilorLuxottica, Meta Platforms, Plug Power, Bloom Energy, Ballard Power, L&G Hydrogen Economy ETF (WKN: A2QMAL), Hershey, Nvidia, Apple, Microsoft, Standard Oil/ExxonMobil, General Electric, NTT, Intel, Texas Instruments, Micron Technology, Eli Lilly, Merck, Air Products, Freeport-McMoran, Keysight, Hess, Williams, EQT, Amundi MDax ETF (WKN: LYX0R1), RWE, National Grid, Rio Tinto, Antofagasta, Infineon, ASML, SAP, Leonardo, Astrazeneca, Merck, Novo Nordisk, Almonty Industries. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Get ready for a thoughtful and down-to-earth conversation with our host, Cathleen O'Sullivan and guest is Michael Frantl, Global Lead for Culture, Engagement, and Performance Solutions at Novo Nordisk about what really shapes strong leadership and why culture matters more than ever. With a career that's taken him across the US, UK, and Scandinavia, Michael shares his real-world experience of building workplace cultures that go beyond posters and buzzwords.   Together, they talk about leading with trust, creating space for belonging, and the small, everyday actions that bring values to life. Michael also reflects on the role of optimism, why control doesn't build connection, and how to make culture feel genuine wherever you work. If you're building a team, leading change, or just trying to show up more intentionally, this episode is for you.   Episode Timeline:  00:00 Introduction 04:36 Life since we last met: moves, parenthood, and big shifts 06:03 Taking the leap, moving to Denmark and starting fresh 10:50 Balancing positivity and reality in leadership 14:09 From rush to reflection: Building quiet moments Into busy days 19:48 Lessons from the family construction business 30:58 Listening to understand: what philosophy taught me about dialogue 39:09 Building workplaces that support people and results 52:06 The power of focus and consistency in culture work 01:03:26 Practical steps for organizations tobBring values to life Key Takeaways: Culture is about what you do every day: Michael and Cathleen stress that company culture isn't just about posters or slogans. It's about how people act and interact every day.    Positivity Matters, but keep it real: Michael talks about finding joy in small moments and connecting with others, but also warns against ignoring challenges.  Leading with intention and space: Move away from micromanaging to truly supporting people. Listening, clear communication, and giving teams room to grow are key.  About Michal Frantl: Michael is a Global Culture, Engagement, & Performance Solutions Lead at Novo Nordisk, based in Copenhagen Denmark. He is an experienced people and culture professional with a focus on culture building and measurement, leadership development/coaching, and employee engagement who has worked across international offices both in house and as an external consultant.   Originally from Wisconsin in the US, he has lived in the US, UK, Sweden, Italy, and Denmark and has a Masters degree in Organizational Behaviour from Birkbeck, University of London. Connect with Michael: https://www.linkedin.com/in/michaelfrantl/   Connect: 
  Find | Cathleen O'Sullivan  Business: cathleenmerkel.com   Email: cmc@cathleenmerkelcoaching.com  LinkedIn: https://www.linkedin.com/in/cathleen-merkel/ Instagram: https://www.instagram.com/legendary_leaders_cathleenos/     FOLLOW LEGENDARY LEADERS ON APPLE, SPOTIFY OR WHEREVER YOU LISTEN TO YOUR PODCASTS.

The Big Unlock Podcast · Aligning AI Fundamentals with User Experience in Pharma – Podcast with Alicia Abella In this episode, Alicia Abella, AI Product Lead at Novo Nordisk, discusses how she is helping drive responsible AI adoption in the pharmaceutical industry. She shares her early experiences in AI, starting with her PhD research at Columbia University on image processing and natural language processing.  At Novo Nordisk, the current focus is on applying AI to commercialization functions including – marketing, legal, and HR – beyond its traditional use in drug discovery. Alicia highlights key use cases such as generative AI for knowledge search, content generation for marketing campaigns, and traditional AI techniques for deriving insights about healthcare providers. She also emphasizes the importance of applying a product mindset to AI development by evaluating user needs, business value, and compliance from the outset. Alicia notes that adding effective governance can help innovation move in the right direction. She also talks about an internal AI Ambassador Program and emphasizes the importance of designing intuitive AI tools to increase adoption. She concludes by discussing future trends in AI, including contextual intelligence, user-centric design, and the opportunity for AI to enhance, rather than replace human decision-making. Take a listen.

Na stronie kampanii „Porozmawiajmy szczerze o otyłości” www.ootylosci.pl czytamy:Otyłość to przewlekła choroba o złożonych przyczynach, która została umieszczona na liście Międzynarodowej Klasyfikacji Chorób (ICD-10) pod numerem E66. Otyłość w Polsce dotyczy 9 milionów dorosłych a blisko 12 mln Polaków w wieku powyżej 20 lat ma nadwagę. Oznacza to, że ponad 20 milionów Polaków ma nadmierną masę ciała. Prognozuje się, że w 2035 roku liczba chorujących na otyłość wzrośnie. Nawet co trzeci Polak będzie się mierzyć z otyłością. - te dane nie mają za zadanie straszyć, a jedynie pokazać, że skala problemu jest istotna. W tym odcinku przyjrzymy się medycznym i psychologicznym konsekwencjom otyłości, a także jakie skuteczne metody leczenia są aktualnie rekomendowane. Jest to odcinek, gdzie swoją wiedzą podzieliły się ze mną specjalistki: dr Anna Ścibisz - kardiolożka i bariatrka oraz Adrianna Sobol - psycholożka, psychotraumatolożka i psychoonkolożka. Patronem tego odcinka jest Novo Nordisk.Czy zdarzyło Wam się słyszeć stygmatyzację osób zmagających się z otyłością? Czy uważacie, że jesteśmy gotowi na społeczne zmiany związane z ocenianiem ciała innych?Montaż: Eugeniusz KarlovLiteraturaKral, T. V., & Rauh, E. M. (2010). Eating behaviors of children in the context of their family environment. Physiology & behavior, 100(5), 567–573. https://doi.org/10.1016/j.physbeh.2010.04.031

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Christoph Kapalschinski über einen Diversity-ETF, neue Verwirrung um Robinhood und Rekordstände zum Independence Day. Außerdem geht es um Data Dog, Commerzbank, SAP, ASML, Novo Nordisk, BASF, Nvidia, Apple, Krispy Kream, Hewlett Packard Enterprise, OpenAI, Yum, Kia, Bitcoin, Société Général, Bank Santander, Coca-Cola, National Bank of Greece, Allianz, Michelin, Unilever, Sony, Yum, Kia, Scottish Mortgage Investment Trust, Berkshire Hathaway, ETF iShares Refinitiv Inclusion and Diversity (WKN A2DVK8), iShares EUR Ultrashort Bond ETF (WKN: A1W375), Xtrackers II EUR Overnight Rate Swap (WKN: DBX0A2), Vanguard FTSE All-World ETF thesaurierend (WKN: A2PKXG) und Vanguard FTSE All-World ETF ausschüttend (WKN: A1JX52). Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This episode covers: Cardiology This Week: A concise summary of recent studies Big data in cardiology Measuring lipids: what clinicians need to know Milestones Host: Perry Elliott Guests: Carlos Aguiar, Karim Lekadir, Kostas Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/1808 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Kostas Koskinas has declared to have potential conflicts of interest to report: speaker fees / honoraria from MSD, Daiichi-Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Perry Elliott Guest: Karim Lekadir Want to watch that episode? Go to: https://esc365.escardio.org/event/1808?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson."

In this episode of Quah (Q & A), Sal, Adam & Justin coach three Pump Heads via Zoom. Mind Pump Fit Tip: 5 tricks to boost protein intake. (2:19) Resistance training alone for fat loss vs. cardio alone for fat loss. (17:47) The potential dangers of Myostatin suppression. (26:44) Do THIS instead of Botox! (32:40) Does Botox affect your ability to empathize? (36:05) Empathy and emotions. (40:46) The best supplement for blood flow. (1:02:37) #ListenerLive question #1 – Will increasing my calories be irresponsible?  I've heard that increasing calories can sometimes help with weight loss if you are under-eating. (1:04:23) #ListenerLive question #2 – If you guys had to pick between prioritizing meals or sleep, which one should I focus on more? (1:19:43) #ListenerLive question #3 – Could my lack of quad development be caused by a hip imbalance? (1:32:09) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com Visit Luminose by Entera for an exclusive offer for Mind Pump listeners! ** July 1st-5th use Code “MPM” for 15% off Flash Sale on individual items. Bundles excluded. ** Visit Joy Mode for an exclusive offer for Mind Pump listeners! ** Enter MINDPUMP at checkout for 20% off your first order. ** July Special: MAPS Split or Anabolic Metabolism Bundle 50% off! ** Code JULY50 at checkout ** Mind Pump #2450: The Smartest Way to Use Protein to Burn Fat & Build Muscle Visit Butcher Box for this month's exclusive Mind Pump offer!  ** Available for a limited time, a curated box pre-filled with Mind Pump's favorite cuts — no guesswork! ButcherBox members who sign up through Mind Pump will receive: $20 OFF their first box, Free chicken breast, ground beef, OR salmon in every box for a whole year! ** Visit Paleovalley for an exclusive offer for Mind Pump listeners! ** Discount is now automatically applied at checkout: 15% off your first order! ** Ninja NC301 CREAMi Ice Cream Maker, for Gelato, Mix-ins, Milkshakes, Sorbet, Smoothie Bowls & More, 7 One-Touch Programs, with (2) Pint Containers & Lids, Compact Size, Perfect for Kids, Silver Weight Lifting Can Burn Fat Just Like Cardio: New Research About Strength Training vs Aerobics A $250 mistake will cost Ozempic maker Novo Nordisk billions Mind Pump #2595: Mike Israetel Unplugged (Explicit Content) Visit NED for an exclusive offer for Mind Pump listeners! ** Code MINDPUMP at checkout for 20% off ** Mind Pump # 2160: Macro Counting Master Class Building Muscle with Adam Schafer – Mind Pump TV Bradley Martyn's Raw Talk - How An Atheist Turned Christian... MAPS Prime Pro Webinar Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Dr. William Seeds (@williamseedsmd) Instagram Michael Israetel (@drmikeisraetel) Instagram Bradley Martyn (@bradleymartyn) Instagram

The Senate has passed the One Big Beautiful Bill, which includes significant cuts to Medicaid. The Supreme Court upholds the Affordable Care Act's preventive services mandate. And, Novo Nordisk inks a new direct-to-consumer partnership. Those stories and more coming up on today's episode of the Gist Healthcare podcast. Hosted on Acast. See acast.com/privacy for more information.

Dare we say digital health is back? The IPOs are IPOing, and startups (at least the AI ones) are back raising mega rounds. In this month's Digital Health Download, Halle and Steve break down the recent headlines, including a blockbuster funding cycle for AI tools, a dramatic breakup between Novo Nordisk and Hims, and why Oregon's new law could shake up how startups structure clinical care.We cover:

Ozempic is one of the most import new medications in a generation. The scientist who created it is a self-described "nerd," who grew up on a farm in Denmark and has no interest in the limelight. Lotte Knudsen started her career working on laundry detergent enzymes, but eventually joined a team at the Danish pharmaceutical company Novo Nordisk that was tasked with looking for new treatments for diabetes. She was convinced that a recently discovered human hormone called GLP-1 could be made into a powerful medication, not only for Type 2 diabetes, but also for weight loss. It took 20 years of hard work and persistence for her and her team to figure it out, but their creation now shows promise as a worthy foe of heart disease, kidney disease, Parkinson's, alcoholism & Alzheimer's as well. In this episode Lotte Knudsen tells her story, and we hear from two of the other scientists who made critical contributions to this revolution in medicine: Mads Thomsen and Daniel Drucker.

Consultorio bursátil de junio de 2025 en el que Adrián Godás y Paco Lodeiro respondemos a las preguntas de los oyentes. Las preguntas generales de este mes son cómo invertir en rupias y yuanes, libros acerca de la teoría del ciclo, a quién seguimos para estar actualizados y sobre cómo ponerse corto del S&P500. Y las dudas sobre empresas y sectores son sobre el cobre e Invanhoe Mining, Boss Energy y Deep Yellow, los riesgos de la IA en videojuegos, Novo Nordisk y United Health, Bloober Team, Ryman Healthcare, TX Group, Warrior Met Coal, Hellenic Exchanges, District Metals y sobre Alphabet. Patrocinador del programa Paleobull, con código de descuento para los oyentes.

Amazon's latest data center will require the same amount of electricity as one million homes. (00:21) Jason Moser and Matt Argersinger join Ricky Mulvey to discuss: - The data center spending boom. - Hims & Hers messy breakup with Novo Nordisk. - Overrated and underrated business stories from the year so far. (19:11) Progyny CEO, Peter Anevski, joins Tim Beyers and Holly Anderson to discuss the growth path ahead for the health benefits company. (31:28) Jason and Matt discuss Disney's box office struggle with “Elio” and offer up two radar stocks: Uber and Otis Worldwide. Companies discussed: AMZN, HIMS, NVO, TSLA, PGNY, DIS, UBER, OTIS Host: Ricky Mulvey Guests: Jason Moser, Matt Argersinger, Tim Beyers, Holly Anderson, Peter Anevski Engineer: Dan Boyd Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, "TMF") do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 126 of the Squeaky Clean Energy podcast features a live recording from the 2025 State Energy Conference. This year, we feature a panel with a few of the region's energy leaders: * Bill Malcolm, AARP, Government Affairs Director - Utilities * Lon Huber, Duke Energy Corporation, Senior Vice President, Pricing and Customer Solutions * Lakin Garth, Smart Electric Power Alliance, Senior Director, Grid Strategy * Matthew Winslow, NC General Assembly, Representative * Jeremy Keltner, Novo Nordisk, Project Manager - Industrial Symbiosis We discuss the fast-changing conversations around load growth and the impacts that meeting demand could have on all customer classes, and the strategies necessary to help ensure we're maintaining affordable electricity rates in North Carolina.  Federal energy tax credit defense action alert: https://p2a.co/wjhjnqx Presented by NC Sustainable Energy Association. Hosted by Matt Abele (Twitter: @MattAbele). Edited by Yash Mistry. Be sure to follow us on Instagram at @nccleanenergy.

Join clinical experts Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU, Madhuri M. Vasudevan, MD, MPH, FACE, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, to learn how the AACE Patient Journey of Diabetes Technology supports people with diabetes in navigating their treatment options with confidence. This patient-friendly resource, developed from AACE clinical guidelines and reviewed by Diabetes Sisters, a leading patient advocacy organization, provides clear and accurate information on diabetes technologies, from glucose monitors to insulin delivery devices. The experts also highlight how members of the endocrine care team are using this tool to empower people with diabetes to manage their journey. This episode is brought to you with the support of Abbott, Novo Nordisk, Medtronic, and Vertex.

The Investing Power Hour is live-streamed every Thursday on the Chit Chat Stocks Podcast YouTube channel at 5:00 PM EST. This week we discussed:(03:38) The Evolution of AI and Its Impact(08:10) Identifying Opportunities and Risks in AI(12:42) The Future of Equity Research with AI(19:08) Market Reactions and Business Models(25:58) Hims and Hers: A Case Study in Market Fragility(34:08) Constellation Software: Investment Insights(40:27) Understanding Human Incentives in Business(45:13) Abercrombie & Fitch: A Brand Revival Story(50:24) The Future of Autonomous Vehicles and Robo-Taxis*****************************************************JOIN OUR NEWSLETTER AND CHAT COMMUNITY: https://chitchatstocks.substack.com/ *********************************************************************Chit Chat Stocks is presented by Interactive Brokers. Get professional pricing, global access, and premier technology with the best brokerage for investors today: https://www.interactivebrokers.com/ Interactive Brokers is a member of SIPC. *********************************************************************Fiscal.ai is building the future of financial data.With custom charts, AI-generated research reports, and endless analytical tools, you can get up to speed on any stock around the globe. All for a reasonable price. Use our LINK and get 15% off any premium plan: ⁠https://fiscal.ai/chitchat *********************************************************************Bluechippers Club is a tight-knit community of stock focused investors. Members share ideas, participate in weekly calls, and compete in portfolio competitions.To join, go to ⁠Blue Chippers and apply! Link: ⁠https://bluechippersclub.com/*********************************************************************Disclosure: Chit Chat Stocks hosts and guests are not financial advisors, and nothing they say on this show is formal advice or a recommendation.

Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; sotatercept phase 3 trial results.

Den kan ikke ses, måles eller vejes. Alligevel er det noget, som mange ansatte i Novo Nordisk taler om i disse turbulente tider for den danske medicinalkæmpe. Den helt særlige Novo Nordisk-ånd, som af mange nuværende og tidligere ansatte bliver fremhævet som rygsøjlen i Novo-koncernen, er under pres efter flere år med tusindvis af nye medarbejdere, vild vækst og uro på ledelsesgangene. Men giver det overhovedet mening at tale om en særlig ånd i en moderne virksomhed med flere tusinde ansatte over hele verden? Deltagere: Gitte Lillelund Bech, public affairs-rådgiver og tidligere forsvarsminister. Rikke Østergaard, erhvervssociolog og forfatter. Søren Linding, erhvervskommentator her på Finans. Vært: Rasmus Bendtsen, redaktør på Finans. Podcastredaktør: Kasper Søegaard. Foto: Thomas Lekfeldt. See omnystudio.com/listener for privacy information.

The count-down's on for New Zealand chemist sales of weight-loss drug Wegovy. A pharmacist has told our newsroom the hunger-suppressing drug will be available on prescription from next Tuesday Novo Nordisk Oceania Senior Medical Director Dr Ana Svensson says the cost of the drug is expected to be around $500, as it's not funded by Pharmac. LISTEN ABOVESee omnystudio.com/listener for privacy information.

On the Heather du Plessis-Allan Drive Full Show Podcast for Thursday, 26 June 2025, Labour MP Willie Jackson reflects on the sudden death of his friend and Maori Party MP Takutai Tarsh Kemp. Should taxpayer money be used to pay for a rugby team? Heather dives into the Moana Pasifika story with NZ Herald senior journalist Kate MacNamara. The drug that made Oprah skinny is coming to New Zealand from next week. Novo Nordisk's Dr Ana Svensson tells Heather Wegovy could potentially help up to 2.8 million overweight Kiwis. NZ Rugby's Mike Hester gets grilled by Heather over the incident of referee abuse that's led to all rugby being postponed by the Horowhenua Kapiti Rugby Union. Plus, the Huddle debates Nimbyism in the light of a Government directive that will see 15 storey apartment buildings in Auckland suburbs. Get the Heather du Plessis-Allan Drive Full Show Podcast every weekday evening on iHeartRadio, or wherever you get your podcasts. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Ein Gerichtsbeschluss zwingt OpenAI, Werbematerialien zu einem Deal mit Jony Ive vorübergehend zurückzuziehen. Die ehemalige CTO von OpenAI, Murati, bereitet sich darauf vor, mit seinem Startup in den Wettbewerb gegen seinen früheren Arbeitgeber zu treten, während im Silicon Valley kleine Teams den neuen Maßstab für Erfolg setzen. Disney geht rechtlich gegen Midjourney vor, um seine Charaktere vor unautorisierter KI-Nutzung zu schützen, und Masayoshi Son plant ein milliardenschweres KI-Roboterzentrum in Arizona. Nik Storonsky von Revolut könnte eine Auszahlung im Stil von Elon Musk erhalten, und Derek Mobley untersucht die Rolle von Algorithmen bei der Ablehnung von Bewerbungen. Deutschland und Italien stehen unter Druck, ihre Goldreserven aus den USA zurückzuführen. Novo Nordisk beendet die Partnerschaft mit Hims & Hers wegen Nachahmerprodukten. Blue Origin expandiert nach Europa, Elon Musk steht erneut im Zentrum rechtlicher Auseinandersetzungen, und Tesla testet fahrerlose Robotaxis in Austin.  Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) OpenAI Jony Ive Gerichtsbeschluss  (00:08:20) Ex OpenAI CTO Startup (00:16:00) KI Tiny Team  (00:25:50) Disney KI Klage (00:30:50) SoftBank Robotik Investition (00:34:40) Revolut Nik Storonsky Aktienanteile (00:37:00) Bewerbungen Algorithmen  (00:42:15) Goldreserven Deutschland (00:46:00) Novo Nordisk Hims & Hers Partnerschaftsende (00:47:30) Google Workspace OpenAI (00:57:20) Schmuddelecke Shownotes OpenAI zieht Werbematerialien zu Jony Ive zurück – techcrunch.com OpenAIs erstes KI-Gerät mit Jony Ive ist kein Wearable – theverge.com Wie Muratis Startup gegen OpenAI konkurrieren will – theinformation.com KI leitet die 'Tiny Team'-Ära im Silicon Valley ein – bloomberg.com Disneys Kampagne zum Schutz von Darth Vader vor KI – bloomberg.com SoftBanks Masayoshi Son plant KI-Roboter-Hub in Arizona – bloomberg.com Apple erwägt Kauf von KI-Startup Perplexity – bloomberg.com Meta verhandelt mit Startup Runway über KI-Recruiting – bloomberg.com Revolut-Chef vor Musk-ähnlicher Auszahlung bei $150 Mrd. Bewertung – ft.com Millionen von Lebensläufen scheitern an Bots. Ein Mann will herausfinden, warum. – wsj.com Deutschland und Italien sollen 245 Mrd. Dollar Gold aus den USA zurückholen – ft.com Texas mit Bitcoin-Reserven – decrypt.co Novo Nordisk beendet Partnerschaft mit Hims & Hers wegen Nachahmer-Wegovy-Medikamenten – on.ft.com OpenAI Google Workspace – theinformation.com Jeff Bezos' Raumfahrtunternehmen: Blue Origin eröffnet Europazentrale in Luxemburg – today.rtl.lu Elon Musk nutzt keinen Computer – wired.com Tesla startet Robotaxi-Fahrten in Austin – techcrunch.com Teslas Robotaxi ist live: erste Reaktionen. – theverge.com Die großen Technologieneuigkeiten von Octopus und BYD, die ignoriert wurden – linkedin.com DeepSeek unterstützt Chinas Militär, umgeht Exportkontrollen – reuters.com Tesla Robotaxi-Vorfälle ziehen Aufmerksamkeit der US-Sicherheitsbehörde auf sich – bloomberg.com Tesla droht Strafe in Frankreich wegen irreführender Aussagen – ft.com Elon Musk besorgt über Realitätseinfluss auf "Grok" KI – futurism.com Cloudflare-CEO: Nutzer überprüfen Quellen von KI-Chatbots nicht – engadget.com

Robert F. Kennedy Jr. testified in front of the House Committee on Energy and Commerce Tuesday, where Democrats confronted the health secretary on hot button issues ranging from his recent overhaul over the CDC's Advisory Committee on Immunization Practices (ACIP) committee, Kennedy's recently published—and error-ridden—MAHA report, and his threat to ban government scientists from publishing in certain medical journals.  Meanwhile, at the FDA, the mass exodus of senior leadership continues. On Monday, Jacqueline Corrigan-Curay, acting head of the Center for Drug Evaluation and Research (CDER), announced her retirement as of July. This follows the ouster of Nicole Verdun—the wildly popular director of the FDA's Office of Therapeutic Products—and her deputy, Rachael Anatol. Their involuntary departure sent shock waves through the biopharma industry, as Verdun had been considered a stabilizing force at the rapidly reshaping agency.  Speaking of the revamped ACIP, the new panel will meet for the first time Wednesday and Thursday to discuss COVID-19 vaccine safety, maternal and pediatric RSV vaccines and more, as experts question the experience and anti-vaccine views of some of Kennedy's recently appointed members and others express concern about the potential politicization of the committee.   On the clinical front, Eli Lilly, Novo Nordisk and others presented new data from their next-generation obesity programs at the American Diabetes Association's 85th Scientific Congress. After failing to impress investors—and meet its own high expectations—with CagriSema, Novo sought to reassure investors by touting a safety profile “in line with the GLP1-RA class,” and Eli Lilly reported that bimagrumab, when used alongside Novo's Wegovy, led to additional weight loss while also preserving muscle mass.  Finally, we recap BIO2025, where Jef Akst, Lori Ellis and Heather McKenzie moderated panels on cell and gene therapy, cybersecurity and AI, and accelerating market entry for rare disease treatments. Relevant to the latter discussion, congressional Republicans dropped the Orphan Cures Act from their version of President Donald Trump's “One Big Beautiful Bill Act,” and congresspeople, including Rep. Gus Bilirakis (R-Fla.) at Tuesday's hearing asked Kennedy to commit to supporting the priority review program for rare pediatric diseases, which expired at the end of last year.  

VALUE FOR VALUE Thank you to the Bowl After Bowl Episode Producers: Sharky, harvhat, ChadF, HeyCitizen, bitpunk.fm, oystein_berge, test toker, Mary-Kate Ultra, Boolysteed, SircussMedia, cottongin, NetNed Homegrown Hits Episode 90 Mary-KateUltra's Discount Blessings! (Substack) 5050pods.com Episode 344 ★ ChadF ★ Bowls With Buds bitpunk_fm unwound BTC Prague Report / bitpunk.fm Cassette Countdown / Stay Awhile - Able and The Wolf Play games with HyperSpaceOut 6pm June 28th Intro/Outro: Raven - Hold On GET FREE STICKERS Send a self-addressed envelope to PO Box 410514 Kansas City, MO 64141 FIRST TIME I EVER… Bowlers called in to discuss the First Time THEY Ever noticed a magic number. Next week, we want to hear about the First Time YOU Ever packed too much. TOP THREE 33 Israel recovers bodies of three Gaza captives as it kills 33 Palestinians (Al Jazeera) Inside historic 33-hour B-2 stealth bomber strike on Iran's nuclear sites (Aviation A2Z) BBC gives Israeli deaths 33 times more coverage, new study reveals (Novara Media) Ukraine war latest: 'It was impossible to look at' - Russian mass missile, drone attack on Kyvi kills at least 9, injures 33 (The Kyiv Independent) Hims & Hers stock plunges 33% as Novo Nordisk ends partnership, citing 'illegal' practices (Investopedia) BEHIND THE CURTAIN Antidepressants can cause heat intolerance, dehydration (New York Post) Study finds higher doses of LSD lead to 'greater reductions in depression' (Cell.com) DEA judge rules against MMJ BioPharma Cultivation's effort to obtain cannabis bulk manufacturing license (FOX) Nebraska Attorney General Mike Hilgers sends cease and desist letters to 204 retailers over mislabeled THC products (Nebraska Examiner) New Jersey finalizes Cannabis Training Academy (NJ.gov) Texas Gov. Greg Abbott signs bill expanding medical weed law, vetoes THC ban (Texas Tribune) Korea Supreme Court declares CBD illegal (Korea JoongAng Daily) METAL MOMENT Tonight, the RevCyberTrucker brings us Aldious' We Are. Follow along with his shenanigans on the Fediverse at  SirRevCyberTrucker@noauthority.social ON CHAIN, OFF CHAIN, COCAINE, SHITSTAIN Bitcoin ad on the Las Vegas strip BitcoinLaws.io Texas ready for $10M Bitcoin purchase after governor signs bill for state reserve (CoinDesk) "Coinmarketcap has been hacked - DO NOT INTERACT" Make it out to a KC Bitcoiners' meetups FUCK IT, DUDE. LET'S GO BOWLING Alabama man allegedly used dead man's identity to buy 33 guns, thousands of rounds (AL.com) 33 unmarked burials potentially found at Legacy Park in Decatur, Georgia (WABE) *Cape Girardeau, Missouri road buckles in the heat (KY3) Michigan bear roamed woods for two years with lid on his neck, but not anymore (The Associated Press) 15-year-old boy struck by lightning in Central Park 'feels lucky' (ABC 7 NY) Giant sphere falls from sky in Indiana after severe weather sweeps through (FOX) Leaders of 'orgasmic meditation' women's wellness company OneTaste convicted in forced labor trial (AP) Man finds out he was married without his knowledge, ex-girlfriend arrested (KLFY) Chinese hotel told 'wake-up service' of red pandas climbing onto guest beds must stop (The Independent UK) Michigan dispensary Bigfoot causes controversy (EH Extra), while another dispensary is offering freebies with proof of Bigfoot sightings (WKFR)

Novo Nordisk parts ways with Hims & Hers, a financials-related stock to get on your radar and more! Jason Moser and Matt Frankel discuss: - Why Novo Nordisk is parting ways with Hims & Hers. - Waymo and Uber's big Atlanta debut. - What the potential tax deduction on autos could mean for consumers and companies. - Matt has a financials-related stock he thinks is worth a closer look. Tickers mentioned: NVO, HIMS, TSLA, UBER, GOOG, GM, ALLY, RKT Host: Jason Moser Guest: Matt Frankel Engineer: Dan Boyd Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 611: Neal and Toby dive into the FICO taking into account consumers Buy Now, Pay Later loans into their credit scores. Also, Novo Nordisk cuts ties with telehealth company Hims & Hers, accusing the mass sale and promotion of Wegovy copycats. Then, job seekers have been using AI to build their resumes for jobs at a rapid pace that is starting to overwhelm job screeners. Meanwhile, Toby examines the trend of SPACs becoming bitcoin treasuries. Finally, a rundown of the latest market reactions from the conflict in Iran. 00:00 - Images of the universe 3:30 - Market update from Middle East conflict 5:00 - Buy now, pay later impacts FICO score 8:30 - Novo Nordisk breaks up with Hims & Hers 12:00 - AI resumes flood the job market 17:00 - Toby's Trends: SPAC Bitcoin treasuries 21:30 - Sprint Finish! Check out https://domainmoney.com/mbdaily and start building your financial plan today We are current clients of Domain Money Advisors, LLC (Domain). Through Domain's sponsorship of Morning Brew Daily, we receive compensation that included a free plan and thus have an incentive to promote Domain Money. Subscribe to Morning Brew Daily for more of the news you need to start your day. Share the show with a friend, and leave us a review on your favorite podcast app. Listen to Morning Brew Daily Here: https://www.swap.fm/l/mbd-note  Watch Morning Brew Daily Here: https://www.youtube.com/@MorningBrewDailyShow Learn more about your ad choices. Visit megaphone.fm/adchoices

On this TCAF Tuesday, Josh Brown sits down with Ric Edelman, Founder of Edelman Financial Engines to discuss: how far Bitcoin has come, the correct Bitcoin allocation, Tokenization, Stablecoins, and much more! Then at 01:03:40 hear an all-new episode of What Are Your Thoughts with ⁠⁠⁠Downtown Josh Brown⁠⁠⁠ and ⁠⁠⁠Michael Batnick⁠⁠⁠! This episode is sponsored by Public. Find out more at: http://public.com/WAYT   Sign up for ⁠⁠⁠The Compound Newsletter⁠⁠⁠ and never miss out! Instagram: ⁠⁠⁠https://instagram.com/thecompoundnews⁠⁠⁠ Twitter: ⁠⁠⁠https://twitter.com/thecompoundnews⁠⁠⁠ LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/the-compound-media/⁠⁠⁠ TikTok: ⁠⁠⁠https://www.tiktok.com/@thecompoundnews⁠⁠⁠ All investing involves the risk of loss, including loss of principal. Brokerage services for US-listed, registered securities, options and bonds in a self-directed account are offered by Public Investing, Inc., member FINRA & SIPC. Public Investing offers a High-Yield Cash Account where funds from this account are automatically deposited into partner banks where they earn interest and are eligible for FDIC insurance; Public Investing is not a bank. Cryptocurrency trading services are offered by Bakkt Crypto Solutions, LLC (NMLS ID 1890144), which is licensed to engage in virtual currency business activity by the NYSDFS. Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrency holdings are not protected by the FDIC or SIPC. *Rate as of 3/5/25. APY is variable and subject to change. **Terms and Conditions apply. Investing involves the risk of loss. This podcast is for informational purposes only and should not be or regarded as personalized investment advice or relied upon for investment decisions. Michael Batnick and Josh Brown are employees of Ritholtz Wealth Management and may maintain positions in the securities discussed in this video. All opinions expressed by them are solely their own opinion and do not reflect the opinion of Ritholtz Wealth Management. The Compound Media, Incorporated, an affiliate of ⁠⁠⁠Ritholtz Wealth Management⁠⁠⁠, receives payment from various entities for advertisements in affiliated podcasts, blogs and emails. Inclusion of such advertisements does not constitute or imply endorsement, sponsorship or recommendation thereof, or any affiliation therewith, by the Content Creator or by Ritholtz Wealth Management or any of its employees. For additional advertisement disclaimers see here ⁠⁠⁠https://ritholtzwealth.com/advertising-disclaimers⁠⁠⁠. Investments in securities involve the risk of loss. Any mention of a particular security and related performance data is not a recommendation to buy or sell that security. The information provided on this website (including any information that may be accessed through this website) is not directed at any investor or category of investors and is provided solely as general information. Obviously nothing on this channel should be considered as personalized financial advice or a solicitation to buy or sell any securities. See our disclosures here: ⁠⁠⁠https://ritholtzwealth.com/podcast-youtube-disclosures/ Learn more about your ad choices. Visit megaphone.fm/adchoices

En este episodio cubrimos los eventos más relevantes antes de la apertura del mercado: • Wall Street sube pese a tensiones en Medio Oriente: Futuros en verde: $SPX +0.8%, $US100 +1.2%, $INDU +0.8%. Los rendimientos del Treasury caen levemente. Israel acusó una violación del alto al fuego y amenaza con represalias, mientras Irán niega nuevos ataques. El permiso para civiles de abandonar refugios en Israel trajo algo de alivio. Hoy se publican datos de precios de vivienda, confianza del consumidor y testifica Powell en el Congreso. • IBM despliega sistema cuántico avanzado en Japón: $IBM y el laboratorio RIKEN inauguraron el primer IBM Quantum System Two fuera de EE.UU., ubicado en Kobe. El sistema utiliza el procesador Quantum Heron de 156 cúbits, el más avanzado de la compañía. Apoyado por NEDO, el proyecto busca combinar supercomputación y computación cuántica en la era post-5G. • Novo Nordisk lanza Wegovy en India: $NVO presentó oficialmente su medicamento para pérdida de peso en el mercado indio. Wegovy se venderá en cinco dosis, con un costo mensual entre $50 y $312. La competencia con $LLY se intensifica tras el lanzamiento de Mounjaro en el país. $NVO +1.95% premarket. • Mastercard y Fiserv integran stablecoin FIUSD: $MA fortalece su alianza con $FI al integrar la stablecoin FIUSD en su red global. La plataforma digital de Fiserv se lanzará en 2025 y busca facilitar soluciones para bancos y adquirentes. $FI +6% premarket tras el anuncio. Una jornada con atención en geopolítica, avances tecnológicos y nuevos frentes en salud y pagos digitales. ¡No te lo pierdas!

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Nando Sommerfeldt über das Talent von Tesla, den Super-Micro-Downer und das letzte große Börsen-Risiko im Iran-Israel-Konflikt. Außerdem geht es um Bitcoin, Volkswagen, Mobileye, UBS Group, Blackrock, WisdomTree WTI Crude Oil 2x Daily Leveraged (A2BC41), WisdomTree WTI Crude Oil (A0KRKU), WisdomTree Brent Crude Oil 3x Daily Short (A3GL7F), Xtrackers MSCI World Energy ETF (WKN: A113FF), SPDR S&P U.S. Energy Select Sector ETF (WKN: A14QB0), SPDR MSCI Europe Energy ETF (WKN: A1191P) Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

USA's præsident Trump meldte mandag ud, at der er indgået våbenhvile mellem Israel og Iran. Danmarks finanspolitiske råderum opjusteres med hele 58 mia. kr. Natos lande på vej mod aftale om 5 pct. Citigroups topchef ser AI som meget større end handelskrig. TDC-salg til kapitalfond granskes. Novo Nordisk opsiger samarbejde med Hims & Hers og aktien får tæsk. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Tesla fährt selbst. Hurra. Ölpreis fällt nach Angriff auf Militärstützpunkte. Hims & Hers fällt nach Absage von Novo Nordisk. Wolfspeed rutscht in die Insolvenz. Northern Trust & BNY werden vielleicht 1 Gigant. Liberty kauft MotoGP. Amrize geht an Börse. JD.com (WKN: A112ST) hat einen neuen Werbekanal: Essen ausliefern. Great Wall Motor (WKN: A0M4X0) war BYD vor BYD. Was kommt jetzt? Diesen Podcast vom 24.06.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Crude oil sliding after Iran's strike on a U.S. base in Qatar. The energy impact, and how the broader markets are reacting. Plus The next move for Novo Nordisk, as the pharma company cuts ties with Hims & Hers. What it means for the weight loss drug space, and how their latest trial data is hitting the stock.Fast Money Disclaimer

But U.S. crude oil futures tumbled and energy stocks posted muted declines after Iran launched missiles at a U.S. base in Qatar and at Iraq. Plus: Tesla shares rose after it debuted its robotaxi service. And stock in Hims & Hers slid after Novo Nordisk ended their partnership. Danny Lewis hosts. Sign up for the WSJ's free What's News newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices

How does tiny, cold Denmark defy the odds to become one of the richest nations? Despite sky-high taxes and a lack of oil wealth, it boasts free education, universal healthcare, and global giants like Novo Nordisk. Unpack the Nordic model, flexicurity, and explore why high taxes haven't crushed growth. Is Denmark's dream sustainable? Watch to find out! Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus a deep dive into Nvidia vs AMD, Dave's analysis of Novo Nordisk's new drug, and what to buy if the market sells off.

Stock market update for June 23, 2025.This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Det kan være svært at bevare optimismen, når nogle af verdens stormagter ser ud til at stå på spring ved våbenarsenalet, men på den anden side ser de globale finansmarkeder dog ikke ud til at være gået helt i panik. Millionærklubben vejrer situationen og debatterer, om man som privat investor bør foretage sig noget. I studiet tjekker teknisk analytiker Lars Persson og Nordnets investeringsøkonom, Per Hansen, markedsåbningen, og med på en telefon fra ADA, American Diabetes Association-konferencen i Chicago, leveres sidste nyt om Novo Nordisk og Eli Lilly af Claus Johansen fra Global Health Invest. Sidst i udsendelsen får vi også et brandvarmt perspektiv på de globale oliemarkeder af Arne Lohmann Rasmussen fra Global Risk Management. Vært: Bodil Johanne GantzelSee omnystudio.com/listener for privacy information.

Meta is throwing out $100m sign-on bonuses for AI engineers!? We chose the wrong career...We unpack it all in another big episode of Equity Mates:Lab-grown meat, now in AustraliaRen is reviewing Novo NordiskSam Gordon, of Australian Property Scout, unpacks buyers agents and buying property inside SuperWant to get involved in the podcast? Record a voice note or send us a message—------Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing - we've got you covered.Keep up with the news moving markets with our daily newsletter and podcast (Apple | Spotify)Check out our latest show: Basis Points (Apple | Spotify | YouTube) and read the accompanying Basis Points email—------Looking for some of our favourite research tools?Read our free ETF Investing HandbookDownload our free 4-step stock checklistFind company information on TIKRScreen the market with GuruFocusResearch reports from Good ResearchTrack your portfolio with Sharesight—------In the spirit of reconciliation, Equity Mates Media and the hosts of Equity Mates Investing acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander people today.—------Equity Mates Investing is a product of Equity Mates Media.This podcast is intended for education and entertainment purposes. Any advice is general advice only, and has not taken into account your personal financial circumstances, needs or objectives. Before acting on general advice, you should consider if it is relevant to your needs and read the relevant Product Disclosure Statement. And if you are unsure, please speak to a financial professional.Equity Mates Media operates under Australian Financial Services Licence 540697. Hosted on Acast. See acast.com/privacy for more information.

El Mundo se Vuelve Loco (y tu Cartera Debería Aprovecharlo) No te voy a mentir. El mundo financiero ahora mismo parece un guion de Tarantino escrito durante un apagón. Tenemos a la Fed jugando al escondite con los tipos de interés, a Trump repartiendo aranceles como si fueran caramelos en un desfile y a un par de países de Oriente Medio decidiendo que los drones son la nueva forma de diplomacia. Caos. Incertidumbre. Ruido. La mayoría de la gente ve esto y sale corriendo. Venden en pánico. Se esconden debajo de la cama con su dinero en efectivo, esperando que pase la tormenta. Ese es el error más grande que puedes cometer. Porque mientras todos miran el fuego, se están perdiendo el mapa del tesoro que se está dibujando entre las llamas. En este episodio, vamos a hacer exactamente lo contrario. Vamos a meternos de cabeza en el ojo del huracán para mostrarte lo que casi nadie está viendo: - La guerra silenciosa por la IA: No es solo Nvidia contra AMD. Es una batalla filosófica entre ecosistemas cerrados y el futuro abierto. Y el ganador no se llevará solo el mercado de chips; se llevará la próxima década de innovación. Te contamos quién está apostando por qué y por qué la jugada de Sam Altman (CEO de OpenAI) lo cambia todo. - El divorcio de Apple con China: Mientras Trump grita en redes sociales, Tim Cook está moviendo sigilosamente miles de millones de dólares y la producción de su producto estrella a la India. No es una retirada, es una de las mayores reconfiguraciones geopolíticas de una cadena de suministro de la historia. Y está sucediendo ahora. - El síndrome del emperador Musk: Tesla, SpaceX, xAI... Elon está construyendo el futuro o quemando dinero a un ritmo que haría llorar a un banco central. Analizamos la fuga de talento en Tesla, la verdad detrás del robotaxi y por qué sus cohetes explosivos son la mejor noticia que han recibido sus competidores. ¿Genio o desastre a punto de ocurrir? Probablemente ambos. - La estupidez de los 1.000 millones de dólares: Te contamos la historia real de cómo Novo Nordisk (los de Ozempic) perdió una fortuna por no pagar una factura de 450 dólares. Es una lección brutal sobre la arrogancia corporativa que te dejará sin palabras. - La burbuja del 46.000%: Hay una empresa por ahí que ha subido un 46.000% sin vender absolutamente nada. Sí, has leído bien. La usaremos como bisturí para diseccionar la psicología de las "meme stocks" y enseñarte a diferenciar una locura de una oportunidad. Este no es un episodio para recitarte las noticias. Es una autopsia en vivo del caos. Porque en finanzas, como en la vida, los momentos de mayor confusión son también los de mayor claridad... si sabes dónde mirar. Dale al play y aprende a bailar bajo la lluvia de billetes. O de misiles. Depende del día.

This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease risk: Framingham Heart Study insights Sudden death in female athletes Mythbusters: Owning a pet reduces the risk of heart disease Host: Susanna Price Guests: Carlos Aguiar, Sabiha Gati, Vasan Ramachandran Want to watch that episode? Go to: https://esc365.escardio.org/event/1809 Want to watch that extended interview on sudden death in athletes? Go to: https://esc365.escardio.org/event/1809?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. The ESC is not liable for any translated content of this video.The English-language always prevails. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel, Susanna Price and Vasan Ramachandran have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Sabiha Gati Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1809?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1809   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Ozempic's still the hottest drug on the planet. But Novo Nordisk's stock? Not so much. It's down nearly 50% from its peak, and investors aren't sure whether to double down or walk away. In today's episode, Finimize Analyst Russell Burns, whose latest research unpack's  what's really going on with the stock, joins the pod.Is this just a healthy correction? Or the kind of long-term opportunity you only get when everyone else is panicking?Try Finimize Pro

Episode 2659: Vinnie Tortorich and Chris Shaffer discuss three different topics that are all promoting mixed messages about health, and more. https://vinnietortorich.com/2025/06/promoting-mixed-messages-episode-2659 PLEASE SUPPORT OUR SPONSORS YOU CAN WATCH ALL THE PODCAST EPISODES ON YOUTUBE -  Promoting Mixed Messages Chris discovered an article in VegNews: a vegan Italian cookbook. (5:00) They divert to a bit of Italian-American history, which has had its challenges. (6:00) Back to the VegNews article: They ponder how an Italian meal can be vegan. (12:15) Vinnie's family grew veggies, but all the Italian meals centered around meat. There was a keto trial—a small trial—but testing high cholesterol. (22:00) They discuss how many studies have been misrepresented by not including countries whose cultural diets contain a lot of meat. Blue Zones has been misrepresented as well. The diets vary, and the level of meat is far more than what tends to be represented. The one thing all the Blue Zone cultures have in common is an active outdoor lifestyle. (37:00) If you want to get rid of heart disease, you must get rid of processed foods. (38:00) Lean Mass Hyper Responders have a different starting point to consider. (40:00) High cholesterol (LDL) in and of itself is not necessarily a problem; you need to look at it in conjunction with other factors. (42:00) The ADA launched the American Obesity Association. Novo Nordisk has contributed funds to the ADA. Novo Nordisk is the company that brought us Wegovy. (51:00) GLP-1s are not a Magic Pill; if they were, they wouldn't have deadly side effects. (52:30) The ADA amended its guidelines to say that GLP-1s should be the “first line of defense” of correction for T2 diabetes, rather than lifestyle. (54:00) The ADA is disengenuous because it receives millions of dollars from Big Food corporations each year to *not* tell you to cut out sugar and processed foods. (55:00) The information the ADA gives cannot entirely be trusted because of the sources of funding it receives. Follow Vinnie on X @vinnietortorich. More News If you are interested in the NSNG® VIP group is currently closed for registration, but you can get on the wait list - Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it!   Eat Happy Italian, Anna's next cookbook, is available!  You can go to  You can order it from .  Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day!  Don't forget you can invest in Anna's Eat Happy Kitchen through StartEngine.  Details are at Eat Happy Kitchen.  There's a new NSNG® Foods promo code you can use! The promo code ONLY works on the NSNG® Foods website, NOT on Amazon. https://nsngfoods.com/   PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere:  Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere:  REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere:  FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: 

⚠️ Warning: Listening to this episode may cause spontaneous inspiration, side effects include rethinking innovation, falling in love with Denmark, and Googling “intelligent bricks.” Meet Anne C. Fleischer — engineer, innovator, former LEO Pharma exec, and now leading Consumer Engagement & New Business Models for Obesity at Novo Nordisk. She grew up in a village so small that your soccer team was whoever showed up to class that day. She wanted to be a helicopter pilot or a doctor, but got motion sickness and couldn't get into med school...... So she built a new path- literally - constructing heart pump mannequins, NFC-enabled pavement tiles, and eventually digital health products that helped millions.

Weight management expert Dr. Megha Poddar explains the science behind weight loss plateaus and why diets alone often fail in this episode of My Weight Live. She explains how the brain's reward system and our biology work to keep weight high, and highlights how obesity medications can play a role in long-term success.This is a must-listen for anyone interested in understanding the complexities of weight management and learning how to support health in a sustainable way.The medical information in this podcast is provided as an information resource only. It is not in any way intended to be nor should you rely on it as a substitute for professional medical evaluation, diagnosis, advice and treatment.This episode was sponsored by Novo Nordisk. It was created independently by My Weight - What to Know with no influence from Novo Nordisk.

Join obesity experts, Dr Robert Kushner, Rameck Hunt, and Michael Knight, as they discuss the impact of social determinants of health (SDOH) on patients with obesity. • Robert Kushner, MD • Rameck Hunt, MD • Michael Knight, MD This podcast is sponsored by Novo Nordisk and is intended for healthcare professionals.  

Join experts in obesity, Dr Robert Kushner, Dr Eden Miller, and Dr Jaime Almandoz as they discuss the complex interactions between various factors that lead to obesity, a chronic, progressive disease with underlying pathophysiology. • Robert Kushner, MD • Eden Miller, MD • Jaime Almandoz, MD This podcast is sponsored by Novo Nordisk and is intended for healthcare professionals.

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.  Further Listening: Trillion Dollar Shot  Why WeightWatchers Wants in on Drugs Like Ozempic   Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kara and Scott discuss former President Joe Biden's cancer diagnosis, and the reactions across the political spectrum. Then, Moody's downgrades the U.S. credit rating, and Republicans try to pass Trump's "Big Beautiful Bill." Plus, Walmart and Apple face Trump's bully tactics, Meta delays its new AI model, and Novo Nordisk's CEO is out amid rising competition in the weight loss drug market. Follow us on Instagram and Threads at @pivotpodcastofficial. Follow us on Bluesky at @pivotpod.bsky.social. Follow us on TikTok at @pivotpodcast. Send us your questions by calling us at 855-51-PIVOT, or at nymag.com/pivot. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this insightful Market Mondays clip, Rashad Bilal, Ian Dunlap, and Troy Millings break down two of the week's biggest financial headlines that could shake up the markets: President Trump's executive order to lower prescription drug prices and Amazon's strategic acquisition of AMD shares. First, the hosts dive deep into the possible long-term impacts of Trump's new executive order aiming to slash prescription drug costs across the board. They discuss the potential winners—everyday consumers in need of lower medication costs—and the possible losers, notably major pharmaceutical companies that may see profit margins squeezed. The conversation covers how this move could spur much-needed innovation within the healthcare sector, but also draws attention to challenges such as lobbying pressure and lengthy litigation. What does this mean for healthcare stocks like Pfizer, Eli Lilly, Novo Nordisk, Johnson & Johnson, CVS, Amgen, and more? The hosts lay out possible outcomes and the bigger economic picture, including references to Mark Cuban's earlier ideas about drug pricing and fair access.Next up, the crew unpacks the real story behind Amazon's much-discussed “purchase” of $84 million in AMD shares. Is this a direct investment or the result of AMD's acquisition of ZT Group International—where Amazon already had stakes? They clarify the technical details and examine how this plays into Amazon's push for self-reliance in AI infrastructure and chip development, following in the footsteps of giants like Apple making their own chips. The discussion also touches on how this integration of hardware and internal resources could position Amazon for even more dominance in the AI race and tech industry at large.Throughout the clip, Rashad, Ian, and Troy provide honest takes on market strategies, investment insights, and the political chess game playing out in real time. From healthcare innovation to tech self-sufficiency, this conversation is a must-watch for investors, entrepreneurs, and anyone wanting to stay ahead of the curve on Wall Street.Don't forget to like, comment, and subscribe for more in-depth market analysis and actionable insights!#MarketMoves #PrescriptionDrugs #HealthcareStocks #TrumpNews #Amazon #AMD #TechStocks #AI #Investing #StockMarket #Finance #BusinessNews #MarkCuban #Pharma #EliLilly #Pfizer #JohnsonAndJohnson #Pharmaceuticals #Innovation #BusinessAnalysis #AmazonPrime #WallStreet #FinancialNewsSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy